Andrew Huxley is the Executive Director for Clinical Research Investigator Engagement – Asia Pacific at Eli Lilly. He oversees the comprehensive investigator site management for Phase I-III Clinical Research Operations and Trial Implementation across various therapeutic areas, including Diabetes, Bio-Medicines, Auto-immune, Dermatology, and Oncology.
Andrew is also responsible for the Global Monitoring Strategy at Lilly which includes Monitoring Innovation.
With over 20 years of experience in the pharmaceutical industry, Andrew is passionate about advancing clinical research to enhance patient outcomes.
He holds a Bachelor’s Degree in Science and an MBA in Project Management and Marketing.